Drugs / LY4515100
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07339722 | Jan → Jul 2026 overdue | — | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07511816 | Apr → Nov 2026 expected | — | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4515100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07511816 ↗ |
| Route | Oral | “given orally” NCT07339722 ↗ |